Loading candles…
Ind-Swift Laboratories Ltd, incorporated in 1995 and headquartered in Chandigarh, operates in the pharmaceutical and bulk drugs industries. The company specializes in pharmaceutical formulations, having exited its Active Pharmaceutical Ingredients (API) and Contract Research and Manufacturing Services (CRAMS) businesses by selling its API division to PI Industries in March 2024. Historically, Ind-Swift was recognized for its leadership in the Macrolide Antibiotic sector. In July 2025, the company concluded a merger with Ind-Swift Limited. Currently, it functions as a debt-free entity focusing exclusively on the global formulations market.
This page is a live market overview for IND SWIFT LABORATORIES LT (INDSWFTLAB) on the NSE. As a listed security, IND SWIFT LABORATORIES LT is tracked in the Healthcare segment of the Indian cash market and is widely followed for price discovery, liquidity and sector exposure. Use this overview to review price action, session ranges and derivatives context for INDSWFTLAB before placing trades on tick2trade.
As of the latest feed, INDSWFTLAB last traded at ₹228.3 on NSE, up ₹1.82 (0.80%) from the previous close of ₹226.48. Today's session range is ₹225 – ₹233.2, against a 52-week band of ₹87.15 – ₹248.45. Traded volume today stands at 2.77L shares.
The overview consolidates an interactive price chart with multiple time ranges, five-level bid and ask depth, recent market headlines, upcoming corporate events for INDSWFTLAB in one place so you do not need multiple screens during the session. Day and 52-week ranges help you judge whether INDSWFTLAB is trading near support, resistance or the middle of its recent band. Volume and depth, when available, add context on how aggressively the name is being bought or sold.
Equity overview pages are built for investors who want a single reference for IND SWIFT LABORATORIES LT before reading news, checking results or sizing a position. Corporate events and headlines in the side column surface catalysts that may explain sudden moves in INDSWFTLAB. Related stocks in the same sector appear at the bottom of the page for quick peer comparison.
For a full option chain with greeks, open-interest bias, max pain and multi-leg strategy tools, open the tick2trade terminal or visit the dedicated INDSWFTLAB option chain page linked from this overview.
| Type | Details | Date |
|---|---|---|
| Results - FY26 | Board meeting intimation to consider and approve the financial results for the period ended Jun 30, 2026 | 10 Aug 2026 |
| Intimation | Intimation of Meeting of the Board of Directors pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requi… | 10 Jul 2026 |
| Audited Results - Q4 & FY26 | To consider and approve the Audited Financial Results for the Quarter and Financial Year ended March 31, 2026 | 28 May 2026 |
| Results - FY25 | To consider and approve, inter alia, the financial results for the period ended December 31, 2025 | 31 Jan 2026 |
| Results - FY25 | To consider and approve the financial results for the period ended September 30, 2025 | 14 Nov 2025 |
| Results - FY25 | To consider and approve the financial results for the period ended Jun 30, 2025 | 13 Aug 2025 |
| Audited Results - Q4-FY25 | INDSWFTLAB: The Board Meeting of the Company is scheduled to be held on August 11, 2025 to inter-alia, consider and approve Audited Financial Results for the… | 11 Aug 2025 |
| Audited Results - Q4 & FY25 | To consider and approve the Standalone & Consolidated Audited Financial Results for the quarter and financial year ended March 31, 2025 | 30 May 2025 |
Tick2trade is a brand/platform owned and operated by Besseggen InfoTech LLP, a SEBI Registered Stock Broker holding Registration No: INZ000213450, Member of NSE (Member Code: 90155) and BSE (Member Code: 6722). Investment in securities market are subject to market risks; read all related documents carefully before investing.